A new stability indicating RP-HPLC based assay method was developed to quantify ivermectin and praziquantel simultaneously and applied effectively to tablets. Methods: The simultaneous assay of ivermectin and praziquantel by RP-HPLC was done using an YMC C18 (250 mm × 4.6 mm, 5 µm) column with a mobile phase mixture of 0.1M disodium hydrogen phosphate (pH 4.5) and acetonitrile (55:45, v/v) using a isocratic flow rate of 1.0 ml/min and measured at 242 nm using photodiode array detector. All parameters were validated following International Conference on Harmonisation (ICH) guiding principles. The method was applied to quantify ivermectin and praziquantel simultaneously in tablets.
Introduction
Ivermectin is a broad spectrum anthelmintic and antiparasitic agent that works against different parasites. 1 Ivermectin is obtained from avermectins. Avermectins is an anti-parasitic agent obtained as a product of fermentation from Streptomyces avermitilis. 2 Ivermectin is used for treating onchocerciasis, strongyloidiasis, enterobiasis, ascariasis, filariasis, trichuriasis and scabies in humans. 3 Also, ivermectin is widely used in domestic animals to give treatment against endoparasites and ectoparasites. 4 Recently, ivermectin is being studied as an antiviral agent against the viruses that causes chikungunya and yellow fever. 5 Ivermectin is chemically known as (2a͘ E,4E,8E)-(5′S, 6S, 6′R,7S, 11R, 13R, 15S, 17aR, 20͘ R, 20aR,20bS)-6′-(S)-sec-butyll 3′, 4′, 5′, 6, 6′, 7, 10, 11, 14, 15, 17a, 20, 20a , 20b-tetradeaca͘ hydro-20,20b-dihydroxy-5′,6,8,19tetra methy͘ l-17-oxospiro [11,15- methano-2H,13H,17Hfuro[4,3,2-pq] [2, 6] -benzodioxacycloocta decin-13,2′-[2H]pyran]-7-yl-2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-l-arabino-hexo pyranosyl)-3-O-methyl-α-l-arab͘ ino-hexopyreanoside ( Figure 1 ). Praziquantel is a broad spectrum antihelmintic agent that works against several cestodes and trematodes. 6 In humans, praziquantel is employed to treat the infections in blood and liver caused by worms. Praziquantel is used in therapy of liver flukes, schistosomiasis and cysticercosis. Praziquantel acts through killing and paralyzing the parasites. 7, 8 This makes them to let loose their grip on blood vessel walls. Then the body eliminates parasites naturally. In dogs, horses and cats, praziquantel is prescribed to treat tapeworm infections, pancreas fluke and blood flukes. [9] [10] [11] Praziquantel is chemically known as (RS)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one ( Figure 2 ). Ivermectin and praziquantel combination is available in paste form (Equimax paste with strength 14.03% praziquantel and 1.87% ivermectin) and tablet dosage form (Ipraz tablet with strength 2 mg ivermectin and 50 mg praziquantel). 12, 13 Equimax is used as dewormer in horses mares, foals, breeding stallions and ponies. It is used to treat and control bots and tapeworms. 14, 15 Ipraz tablets are used as dewormer in dogs. These tablets are prescribed to treat and control flat worms and round worms in dogs. 13 The literature described quite a few analytical methods for the estimation of ivermectin and praziquantel in combination with other drugs. These methods are based on techniques, such as ultraviolet spectroscopy, 16 diffuse reflectance spectroscopy, 16 high performance liquid chromatography, [17] [18] [19] [20] [21] high performance thin layer chromatography 22 and high performance liquid chromatography with tandem mass spectrometry. 23 To the best of our knowledge, till now only one HPLC method for the simultaneous quantification of ivermectin and praziquantel in Equimax paste is reported. 24 Quantification of ivermectin and praziquantel simultaneously in tablets using a stability indicating RP-HPLC method is not reported. Therefore, a stability indicating RP-HPLC method for quantifying ivermectin and praziquantel simultaneously in tablets has been proposed and validated based on International Conference on Harmonisation (ICH) requirements.
Materials and methods

HPLC instrumentation
The HPLC system consists of a Waters alliance HPLC module quaternary pump, a rheodyne sample injection valve with a 10 μl sample loop, a YMC C18 (5 μm particle size, 4.6 mm by 250 mm) analytical column, and a Waters photodiode array detector. Acquisition and interpretation of chromatographic data was performed with Empower2 version software.
Chemicals, solvents and suppliers
HPLC grade acetonitrile was procured from Merck India Ltd, Mumbai, India. Remaining other chemicals that were used in this study were analytical regent grade and obtained from SD. Fine Chemicals Ltd., Mumbai, India. The used chemicals were include disodium hydrogen phosphate, sodium hydroxide, hydrochloride, hydrogen peroxide and orthophosphoric acid. Milli-Q water were obtained from Millipore system.
Reference standards of ivermectin and praziquantel and their tablet dosage forms
Reference standards of ivermectin and praziquantel were procured from Rainbow Pharma Training Labs, Hyderabad, India. Ipraz tablets with strength 2 mg ivermectin and 50 mg praziquantel (Virbac animal health, Mumbai, India) were purchased from a local pharmacy market.
Chromatographic conditions for assay
So as to produce reproducible and reliable chromatographic results, following conditions were used: 0.1 M Na2HPO4: acetonitrile (55:45 v/v) as mobile phase, 1 ml/min isocratic flow rate, 25 o C column temperature, 242 nm detection wavelength and 10 µl injection volume.
Ivermectin and praziquantel stock solution
Ivermectin and praziquantel stock solution was prepared by dissolving 2 mg of ivermectin and 50 mg of praziquantel in 100 ml of mobile phase. Final concentration of stock solution is 20 µg/ml ivermectin and 500 µg/ml praziquantel.
Solutions for calibration curve and validation
Five solutions with following concentrations were prepared for calibration curves of ivermectin and praziquantel by diluting stock solution appropriately with the mobile phase: Solution I: 1 µg/ml ivermectin and 25 µg/ml praziquantel Solution II: 1.5 µg/ml ivermectin and 37.5 µg/ml praziquantel Solution III: 2 µg/ml ivermectin and 50 µg/ml praziquantel Solution IV: 2.5 µg/ml ivermectin and 62.5 µg/ml praziquantel N N O O Solution V: 3 µg/ml ivermectin and 75 µg/ml praziquantel Working solution for validation studies was prepared through diluting stock solution with mobile phase to achieve a final concentration of 2 µg/ml ivermectin and 50 µg/ml praziquantel.
Tablet solution preparation
Ten tablets were powdered. Exactly weighed tablet powder equal to 2 mg of ivermectin and 50 mg of praziquantel was dissolved in 100 ml of mobile phase (concentration -20 µg/ml ivermectin and 500 µg/ml praziquantel). The solution was homogenized thoroughly using sonication for 20 min. The obtained solution was diluted aptly with the mobile phase to get a final concentration of 2 µg/ml ivermectin and 50 µg/ml praziquantel for analysis following filtration via a 0.45 μm membrane filter.
Calibration graphs of ivermectin and praziquantel
Calibration graphs of ivermectin and praziquantel were prepared as per the guidelines of ICH. Five calibration solutions in the concentration range 1-3 µg/ml of ivermectin and 25-75 µg/ml of praziquantel were prepared. 10 μl volume of each calibration solution was injected into the system under the assay conditions explained above. The peak areas of ivermectin and praziquantel were determined at 242 nm. Calibration graphs were plotted with peak area against concentration. The evaluation of linearity was made with linear regression analysis.
Assay of ivermectin and praziquantel in marketed tablet
Tablet solution with a concentration of 2 µg/ml ivermectin and 50 µg/ml praziquantel was prepared and analyzed using described assay conditions through triplicate injections into the system. The peak areas of ivermectin and praziquantel were determined. The content of ivermectin and praziquantel in tablets was estimated using the corresponding linear regression or corresponding calibration curve.
Stress degradation of ivermectin and praziquantel
Guidelines Q1A (R2) was followed to study the stress degradation. 25 Ivermectin and praziquantel tablet stock solution (20 µg/ml ivermectin and 500 µg/ml praziquantel) was used for degradation to establish an indication for the method's stability indicating property and specificity.
For acid, base, water and hydrogen peroxide induced degradation, 10 ml of 0.1N HCl, 10 ml of 0.1N NaOH, 10 ml of distilled water and 10 ml of 30% hydrogen peroxide, respectively were added separately into 10 ml of ivermectin and praziquantel tablet stock solution at room temperature and the mixtures were sonicated for 30 min. After specified period of degradation, the mixture was diluted to 100 ml with mobile phase for analysis. For photo and thermal degradation, 10 ml of ivermectin and praziquantel tablet stock solution was exposed to sunlight for 24 h and 105 o C for 30 min in hot air oven, respectively. Following degradation, the degraded solutions were diluted to 100 ml with mobile phase for analysis. Before injecting the degraded solutions into system, they were filtered through 0.45 μm membrane filter.
Results and discussion
Assay method development Various stationary phases (Waters C18, Xterra C18 and YMC C18) were used to check the chromatogram with acceptable peak shape, tailing factor and plate count for reproducibility at 25 o C. Various trials have been performed by using 0.1% orthophosphoric acid/methanol, 0.1M sodium dihydrogen phosphate/methanol, 0.1M disodium hydrogen phosphate/acetonitrile combinations in different ratios, different pH ranges and different flow rates. The trails were done to optimize the mobile phase composition, pH and flow rate for the separation of ivermectin and praziquantel peaks with acceptable resolution and with good peak shape. Based on the observations and conclusions obtained from the good enough number of chromatographic trials, a particular set of chromatographic conditions were optimized and found to be suitable for simultaneous estimation of ivermectin and praziquantel. The optimized chromatographic conditions are as follows:  Column (stationary phase) : YMC C18 (250 mm x 4.6 mm, 5 µm particle size)  Mobile phase composition and ratio: 0.1M disodium hydrogen phosphate and acetonitrile combination in ratio 55:45 (v/v)  Mobile phase flow rate : 1.0 ml/min The chromatogram of ivermectin and praziquantel obtained after method optimization was given in Figure 3 . , September 2019, 25(3) , 254-261 | 257 
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Method validation
The optimized method was validated as per ICH Q2 (R1) guidelines. 26 The validation parameters evaluated are given below.
System suitability
Test parameters were assessed by injecting 10 μl of ivermectin and praziquantel working solution 6 times, with a concentration of 2 µg/ml ivermectin and 50 µg/ml praziquantel. As per the chromatograms obtained, parameters such as injection precision for working solution (relative standard deviation of peak areas and retention times of ivermectin and praziquantel), theoretical plates for working solution, resolution for working solution and tailing factor for working solution were determined, and stated in Table 1 . The values are within the acceptable limit. Hence the system is suitable for the assay of ivermectin and praziquantel simultaneously.
Linearity
The assay method reported, gave good quality linear detectable response in the range of 1 to 3 µg/ml (ivermectin) and 25 to 75 µg/ml (praziquantel) with coefficient of regression (R 2 ) of 0.9998 (ivermectin) and 0.9999 (praziquantel) with well resolved ivermectin and praziquantel peaks. The regression equation (PA = mC + I, where 'PA' is peak area, 'm' is slope, 'C' is concentration of drug and 'I' is intercept) is: PA = 28621 C + 33.50 ----ivermectin PA = 73050 C + 63.92 ----praziquantel These values indicated good correlation between peak area and drug concentration.
Limit of detection and limit of quantification
The limits of detection (LOD) and quantification (LOQ) were determined as signal to noise ratio of 3:1 and 10:1, respectively for ivermectin and praziquantel. LOD value for ivermectin and praziquantel was calculated as 0.010 µg/ml and 0.046 µg/ml, and LOQ value for ivermectin and praziquantel was 0.033 µg/ml and 0.155 µg/ml, respectively. The values of LOD and LOQ for ivermectin and praziquantel obtained proved adequate sensitivity of the assay method. 
Selectivity
The developed assay method was examined for selectivity to ensure there was no interference from the components of solvent system used and common tablet excipients. The mobile phase (blank), placebo (blank), working solution (2 µg/ml ivermectin and 50 µg/ml praziquantel) and tablet solution (2 µg/ml ivermectin and 50 µg/ml praziquantel) were injected. The obtained respective chromatograms were compared (Figure 4 ). No interfering peaks were observed in the mobile phase (blank) and placebo (blank) chromatograms at retention times of ivermectin and praziquantel. The results proved the selectivity of the assay method.
Precision and accuracy
Both precision and accuracy of the assay method were evaluated. Precision and accuracy tests were done using working solution (2 µg/ml ivermectin and 50 µg/ml praziquantel) and executed in six replicates. Precision and accuracy are expressed by the value of percent relative standard deviation and percent assay, respectively. Precision is stated well if percent relative standard deviation is not greater than 2%. The percent relative standard deviation is 0.078% and 0.079% for ivermectin and 0.244% and 0.241% for praziquantel. The accuracy is considered good, as percent assay in the range of 98.90-99.62%. The average of percent assay is 99.51% and 99.20% for ivermectin and praziquantel, respectively. The precision and accuracy data of ivermectin and praziquantel are shown in Table 2 .
Recovery
To confirm the recovery of the assay method, the results of assay of ivermectin and praziquantel were evaluated as the percentage of recovery of known concentration of ivermectin and praziquantel spiked to the preanalyzed tablet sample. Each sample was injected three times and recovery was assessed in the range of 50%, 100% and 150% for ivermectin and praziquantel. The results are depicted in Table 3 . , September 2019, 25(3) , 254-261 | 259
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High recovery pointed out that the assay method had a good degree of selectivity and accuracy.
Robustness
Robustness test was done by making changes in assay conditions. These changes included: flow rate (±0.2 ml/min), ratio of acetonitrile in mobile phase (±5%), column temperature (± 2 o C), pH of mobile phase (±0.2 units) and detection wavelength (± 2 nm). During robustness testing, the system suitability parameter values were determined. The values in all changed conditions are within the acceptable limit (Table 4 ). Hence the method is robust.
Specificity and stress degradation study
Stability indicating ability and specificity of the assay method were demonstrated through the stress degradation studies. The degradation tests employed hydrolysis (acid, base and water), oxidation (hydrogen peroxide), dry heat and direct sun light. The percentage recovery, percentage degradation, purity angle and purity threshold values of ivermectin and praziquantel were calculated. The obtained results from degradation tests have been depicted in Table 5 . Degradation was observed in all the stress conditions applied. The developed method was able to separate the peaks of degradants from the peaks of ivermectin and praziquantel, indicating that the method had suitable specificity and stability indicating ability ( Figure 5 ). Peak purity of ivermectin and praziquantel peaks were evaluated by photodiode array detector. The less value of purity angle than purity threshold indicated an excellent degree of purity of ivermectin and praziquantel peaks. 
Application of assay method to tablet formulation
Applicability of the developed assay method was demonstrated by determining ivermectin and praziquantel content in marketed tablet dosage form. The recovery of ivermectin and praziquantel were determined in triplicates. The determined results were satisfactory with excellent recovery of the labeled amount (Table 6 ). 
Conclusion
A stability indicating RP-HPLC based assay method was developed and validated for the assay of ivermectin and praziquantel in tablet and bulk forms. Linearity and remaining other validation parameters were good enough in the concentration ranges of 1-3 μg/ml and 25-75 μg/ml for ivermectin and praziquantel, respectively. The results of stress degradation divulged the specificity and stability indicating property of the method. The method was applied to tablet form and demonstrated to be accurate and precise for the assay of ivermectin and praziquantel simultaneously and its applicability for the quality control of ivermectin and praziquantel.
